We are live on ! Find out more
IC

Ikarian Capital Portfolio holdings

AUM $1.23B
1-Year Est. Return 600.17%
This Fund
S&P 500
This Quarter Est. Return
+7.52%
1 Year Est. Return
+600.17%
3 Year Est. Return
+5,763.15%
5 Year Est. Return
+15,527.6%
10 Year Est. Return
–
AUM
$1.33B
AUM Growth
+$713M
Cap. Flow
+$1.03B
Cap. Flow %
77.19%
Top 10 Hldgs %
46.07%
Holding
196
New
82
Increased
39
Reduced
17
Closed
45

Top Buys

Rank Stock Value
1
ZGNX
Zogenix, Inc.
ZGNX
+$20M
2
XLRN
Acceleron Pharma
XLRN
+$18.6M
3
TARA icon
Protara Therapeutics
TARA
+$12.9M
4
BTAI icon
BioXcel Therapeutics
BTAI
+$12M
5
VSTM icon
Verastem
VSTM
+$11M

Top Sells

Rank Stock Value
1
APTO
Aptose Biosciences, Inc.
APTO
+$5.72M
2
AUPH icon
Aurinia Pharmaceuticals
AUPH
+$4.63M
3
TGTX icon
TG Therapeutics
TGTX
+$3.51M
4
KALA icon
KALA BIO
KALA
+$3.39M
5
ARQL
Arqule Inc
ARQL
+$2.97M

Sector Composition

Rank Sector Weight
1 Healthcare 19.74%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
WVE icon
176
PUT
Wave Life Sciences
WVE
$1.09B
– –
-300,000
Closed -$2.4M
XFOR icon
177
X4 Pharmaceuticals
XFOR
$375M
– –
-333
Closed -$107K
PVLA
178
CALL
Palvella Therapeutics
PVLA
$1.99B
– –
-275
Closed -$80K
ONC
179
PUT
BeOne Medicines Ltd
ONC
$32.8B
– –
-77,000
Closed -$12.8M
TVRD
180
PUT
Tvardi Therapeutics
TVRD
$19.7M
– –
-117
Closed -$68K
ITCI
181
CALL
DELISTED
Intra-Cellular Therapies Inc.
ITCI
– –
-267,100
Closed -$9.16M
ITCI
182
PUT
DELISTED
Intra-Cellular Therapies Inc.
ITCI
– –
-924,100
Closed -$31.7M
DCPH
183
CALL
DELISTED
Deciphera Pharmaceuticals, Inc. Common Stock
DCPH
– –
-100,000
Closed -$6.22M
ALPN
184
DELISTED
Alpine Immune Sciences Inc
ALPN
– –
-4,739
Closed -$18K
MRTX
185
CALL
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
– –
-100,000
Closed -$12.9M
MTEM
186
DELISTED
Molecular Templates, Inc.
MTEM
– –
-2,727
Closed -$572K
APTO
187
DELISTED
Aptose Biosciences, Inc.
APTO
– –
-2,244
Closed -$5.72M
CCXI
188
DELISTED
ChemoCentryx, Inc.
CCXI
– –
-46,423
Closed -$1.97M
SRRA
189
DELISTED
Sierra Oncology, Inc. Common Stock
SRRA
– –
-9,660
Closed -$132K
GWPH
190
CALL
DELISTED
GW Pharmaceuticals Plc American Depositary Shares
GWPH
– –
-100,000
Closed -$10.5M
EIDX
191
CALL
DELISTED
Eidos Therapeutics, Inc. Common Stock
EIDX
– –
-100,000
Closed -$5.74M
AIMT
192
DELISTED
Aimmune Therapeutics
AIMT
– –
-40,000
Closed -$1.34M
ARQL
193
CALL
DELISTED
Arqule Inc
ARQL
– –
-497,700
Closed -$9.93M
ARQL
194
DELISTED
Arqule Inc
ARQL
– –
-148,930
Closed -$2.97M
ARQL
195
PUT
DELISTED
Arqule Inc
ARQL
– –
-336,400
Closed -$6.71M
BHVN
196
DELISTED
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
– –
-642
Closed -$29.4K
4 5 6 7
8

Similar funds

FLII
First Long Island Investors Jericho, New York $1.23B AUM 14.42% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return
HCA
Harbor Capital Advisors Chicago, Illinois $1.23B AUM 30.56% 1-Year Est. Return
GX
Greylock XIV Menlo Park, California $1.24B AUM
WCM
Windward Capital Management Los Angeles, California $1.23B AUM 23.17% 1-Year Est. Return
MP
Mangrove Partners Greenwich, Connecticut $1.24B AUM 41.74% 1-Year Est. Return
IA
Inspire Advisors Meridian, Idaho $1.23B AUM 18.62% 1-Year Est. Return
IB
Intrust Bank Wichita, Kansas $1.23B AUM 26.34% 1-Year Est. Return

Ikarian Capital's Q1 2020 Portfolio in Review

As of Q1 2020, Ikarian Capital held 196 positions worth $1.33B, up 115% from $617M the previous quarter. Its ten largest holdings account for 46% of the portfolio.

Ikarian Capital deployed $1.03B of net new capital in Q1 2020, opening 82 new positions and adding to 39 existing holdings. Its largest new stake was Zogenix, Inc.: 549,459 shares worth $13.6M.

By sector, the portfolio is most concentrated in Healthcare at 20% of assets, up from 16% a quarter earlier.

On the sell side, the largest reduction was Aurinia Pharmaceuticals, an estimated $4.63M trimmed.

  • Ikarian Capital's largest Q1 2020 buy was Zogenix, Inc.: 549,459 shares worth $13.6M.
  • Ikarian Capital added most to Protara Therapeutics in Q1 2020, an estimated $12.9M increase.
  • Ikarian Capital's biggest Q1 2020 reduction was Aurinia Pharmaceuticals, cutting an estimated $4.63M.
  • Ikarian Capital fully exited Aptose Biosciences, Inc. in Q1 2020, selling an estimated $5.72M.
  • Ikarian Capital's ten largest holdings make up 46% of its $1.33B portfolio in Q1 2020.
  • Ikarian Capital opened 82 new positions and closed 45 in Q1 2020.
  • Ikarian Capital's portfolio value rose 115% quarter-over-quarter to $1.33B.

Based on Ikarian Capital's 13F filing for Q1 2020, filed 15 May 2020.